Serum progranulin levels are elevated in patients with systemic lupus erythematosus, reflecting disease activity

Atsushi Tanaka, Hiroshi Tsukamoto, Hiroki Mitoma, Chikako Kiyohara, Naoyasu Ueda, Masahiro Ayano, Shun ichiro Ohta, Yasushi Inoue, Yojirou Arinobu, Hiroaki Niiro, Takahiko Horiuchi, Koichi Akashi

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Introduction: Progranulin (PGRN) is the precursor of granulin (GRN), a soluble cofactor for toll-like receptor 9 (TLR9) signaling evoked by oligonucleotide (CpG)-DNA. Because TLR9 signaling plays an important role in systemic lupus erythematosus (SLE), we investigated whether PGRN is involved in the pathogenesis of SLE.Methods: We measured concentrations of serum PGRN and interleukin-6 (IL-6) with enzyme-linked immunosorbent assay (ELISA) in patients with SLE (n = 68) and in healthy controls (n = 60). We assessed the correlation between the serum PGRN levels and established disease-activity indexes. The sera from the patients with high PGRN titers (>80 ng/ml) at the initial evaluation were reevaluated after the disease was ameliorated by treatment. We also measured the IL-6 concentration secreted by peripheral blood mononuclear cells (PBMCs) incubated with (a) oligonucleotide (CpG-B) in the presence or absence of recombinant human PGRN (rhPGRN); and (b) lupus sera in the presence or absence of a neutralizing anti-PGRN antibody.Results: Serum PGRN levels were significantly higher in SLE patients than healthy controls. Their levels were significantly associated with activity of clinical symptoms. They also significantly correlated with values of clinical parameters, including the SLE Disease Activity Index and anti-double-stranded DNA antibody titers, and inversely with CH50, C3, and C4 levels. Moreover, serum PGRN levels significantly decreased after successful treatment of SLE. The rhPGRN significantly upregulated the production of IL-6 by PBMCs stimulated with CpG-B. Patients' sera stimulated production of IL-6 from PBMCs, which was significantly impaired by neutralization of PGRN. The serum PGRN levels significantly correlated with the serum IL-6 levels.Conclusions: Serum PGRN could be a useful biomarker for disease activity of SLE. PGRN may be involved in the pathogenesis of SLE partly by enhancing the TLR9 signaling.

Original languageEnglish
Article numberR244
JournalArthritis Research and Therapy
Volume14
Issue number6
DOIs
Publication statusPublished - Nov 11 2012

Fingerprint

Systemic Lupus Erythematosus
Serum
Toll-Like Receptor 9
Interleukin-6
Blood Cells
Oligonucleotides
DNA
Neutralizing Antibodies
Anti-Idiotypic Antibodies
Biomarkers
Enzyme-Linked Immunosorbent Assay
Antibodies
Therapeutics

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Serum progranulin levels are elevated in patients with systemic lupus erythematosus, reflecting disease activity. / Tanaka, Atsushi; Tsukamoto, Hiroshi; Mitoma, Hiroki; Kiyohara, Chikako; Ueda, Naoyasu; Ayano, Masahiro; Ohta, Shun ichiro; Inoue, Yasushi; Arinobu, Yojirou; Niiro, Hiroaki; Horiuchi, Takahiko; Akashi, Koichi.

In: Arthritis Research and Therapy, Vol. 14, No. 6, R244, 11.11.2012.

Research output: Contribution to journalArticle

@article{2745a81980b540f7bd34c2926546ce3f,
title = "Serum progranulin levels are elevated in patients with systemic lupus erythematosus, reflecting disease activity",
abstract = "Introduction: Progranulin (PGRN) is the precursor of granulin (GRN), a soluble cofactor for toll-like receptor 9 (TLR9) signaling evoked by oligonucleotide (CpG)-DNA. Because TLR9 signaling plays an important role in systemic lupus erythematosus (SLE), we investigated whether PGRN is involved in the pathogenesis of SLE.Methods: We measured concentrations of serum PGRN and interleukin-6 (IL-6) with enzyme-linked immunosorbent assay (ELISA) in patients with SLE (n = 68) and in healthy controls (n = 60). We assessed the correlation between the serum PGRN levels and established disease-activity indexes. The sera from the patients with high PGRN titers (>80 ng/ml) at the initial evaluation were reevaluated after the disease was ameliorated by treatment. We also measured the IL-6 concentration secreted by peripheral blood mononuclear cells (PBMCs) incubated with (a) oligonucleotide (CpG-B) in the presence or absence of recombinant human PGRN (rhPGRN); and (b) lupus sera in the presence or absence of a neutralizing anti-PGRN antibody.Results: Serum PGRN levels were significantly higher in SLE patients than healthy controls. Their levels were significantly associated with activity of clinical symptoms. They also significantly correlated with values of clinical parameters, including the SLE Disease Activity Index and anti-double-stranded DNA antibody titers, and inversely with CH50, C3, and C4 levels. Moreover, serum PGRN levels significantly decreased after successful treatment of SLE. The rhPGRN significantly upregulated the production of IL-6 by PBMCs stimulated with CpG-B. Patients' sera stimulated production of IL-6 from PBMCs, which was significantly impaired by neutralization of PGRN. The serum PGRN levels significantly correlated with the serum IL-6 levels.Conclusions: Serum PGRN could be a useful biomarker for disease activity of SLE. PGRN may be involved in the pathogenesis of SLE partly by enhancing the TLR9 signaling.",
author = "Atsushi Tanaka and Hiroshi Tsukamoto and Hiroki Mitoma and Chikako Kiyohara and Naoyasu Ueda and Masahiro Ayano and Ohta, {Shun ichiro} and Yasushi Inoue and Yojirou Arinobu and Hiroaki Niiro and Takahiko Horiuchi and Koichi Akashi",
year = "2012",
month = "11",
day = "11",
doi = "10.1186/ar4087",
language = "English",
volume = "14",
journal = "Arthritis Research and Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "6",

}

TY - JOUR

T1 - Serum progranulin levels are elevated in patients with systemic lupus erythematosus, reflecting disease activity

AU - Tanaka, Atsushi

AU - Tsukamoto, Hiroshi

AU - Mitoma, Hiroki

AU - Kiyohara, Chikako

AU - Ueda, Naoyasu

AU - Ayano, Masahiro

AU - Ohta, Shun ichiro

AU - Inoue, Yasushi

AU - Arinobu, Yojirou

AU - Niiro, Hiroaki

AU - Horiuchi, Takahiko

AU - Akashi, Koichi

PY - 2012/11/11

Y1 - 2012/11/11

N2 - Introduction: Progranulin (PGRN) is the precursor of granulin (GRN), a soluble cofactor for toll-like receptor 9 (TLR9) signaling evoked by oligonucleotide (CpG)-DNA. Because TLR9 signaling plays an important role in systemic lupus erythematosus (SLE), we investigated whether PGRN is involved in the pathogenesis of SLE.Methods: We measured concentrations of serum PGRN and interleukin-6 (IL-6) with enzyme-linked immunosorbent assay (ELISA) in patients with SLE (n = 68) and in healthy controls (n = 60). We assessed the correlation between the serum PGRN levels and established disease-activity indexes. The sera from the patients with high PGRN titers (>80 ng/ml) at the initial evaluation were reevaluated after the disease was ameliorated by treatment. We also measured the IL-6 concentration secreted by peripheral blood mononuclear cells (PBMCs) incubated with (a) oligonucleotide (CpG-B) in the presence or absence of recombinant human PGRN (rhPGRN); and (b) lupus sera in the presence or absence of a neutralizing anti-PGRN antibody.Results: Serum PGRN levels were significantly higher in SLE patients than healthy controls. Their levels were significantly associated with activity of clinical symptoms. They also significantly correlated with values of clinical parameters, including the SLE Disease Activity Index and anti-double-stranded DNA antibody titers, and inversely with CH50, C3, and C4 levels. Moreover, serum PGRN levels significantly decreased after successful treatment of SLE. The rhPGRN significantly upregulated the production of IL-6 by PBMCs stimulated with CpG-B. Patients' sera stimulated production of IL-6 from PBMCs, which was significantly impaired by neutralization of PGRN. The serum PGRN levels significantly correlated with the serum IL-6 levels.Conclusions: Serum PGRN could be a useful biomarker for disease activity of SLE. PGRN may be involved in the pathogenesis of SLE partly by enhancing the TLR9 signaling.

AB - Introduction: Progranulin (PGRN) is the precursor of granulin (GRN), a soluble cofactor for toll-like receptor 9 (TLR9) signaling evoked by oligonucleotide (CpG)-DNA. Because TLR9 signaling plays an important role in systemic lupus erythematosus (SLE), we investigated whether PGRN is involved in the pathogenesis of SLE.Methods: We measured concentrations of serum PGRN and interleukin-6 (IL-6) with enzyme-linked immunosorbent assay (ELISA) in patients with SLE (n = 68) and in healthy controls (n = 60). We assessed the correlation between the serum PGRN levels and established disease-activity indexes. The sera from the patients with high PGRN titers (>80 ng/ml) at the initial evaluation were reevaluated after the disease was ameliorated by treatment. We also measured the IL-6 concentration secreted by peripheral blood mononuclear cells (PBMCs) incubated with (a) oligonucleotide (CpG-B) in the presence or absence of recombinant human PGRN (rhPGRN); and (b) lupus sera in the presence or absence of a neutralizing anti-PGRN antibody.Results: Serum PGRN levels were significantly higher in SLE patients than healthy controls. Their levels were significantly associated with activity of clinical symptoms. They also significantly correlated with values of clinical parameters, including the SLE Disease Activity Index and anti-double-stranded DNA antibody titers, and inversely with CH50, C3, and C4 levels. Moreover, serum PGRN levels significantly decreased after successful treatment of SLE. The rhPGRN significantly upregulated the production of IL-6 by PBMCs stimulated with CpG-B. Patients' sera stimulated production of IL-6 from PBMCs, which was significantly impaired by neutralization of PGRN. The serum PGRN levels significantly correlated with the serum IL-6 levels.Conclusions: Serum PGRN could be a useful biomarker for disease activity of SLE. PGRN may be involved in the pathogenesis of SLE partly by enhancing the TLR9 signaling.

UR - http://www.scopus.com/inward/record.url?scp=84868597292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868597292&partnerID=8YFLogxK

U2 - 10.1186/ar4087

DO - 10.1186/ar4087

M3 - Article

C2 - 23140401

AN - SCOPUS:84868597292

VL - 14

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

IS - 6

M1 - R244

ER -